Abstract | BACKGROUND: OBJECTIVE: METHODS: The Cochrane trial database, Medline, Embase, were searched systematically, and approximately 20 respiratory journals and conference abstracts were searched manually. Language of publication was limited to English. included tiotropium, COPD, anticholinergic, safety and adverse events. CONCLUSION: A large body of evidence is available at present on the safety and efficacy of tiotropium in COPD, with dry mouth being the most common adverse event. Reviews of serious adverse event data in the literature have reported that tiotropium is safe and that the incidence of these events is the same as with placebo. Tiotropium is a convenient treatment for COPD with a good clinical efficacy and safety profile.
|
Authors | Pierachille Santus, Fabiano Di Marco |
Journal | Expert opinion on drug safety
(Expert Opin Drug Saf)
Vol. 8
Issue 3
Pg. 387-95
(May 2009)
ISSN: 1744-764X [Electronic] England |
PMID | 19505267
(Publication Type: Journal Article, Review)
|
Chemical References |
- Bronchodilator Agents
- Scopolamine Derivatives
- Tiotropium Bromide
|
Topics |
- Animals
- Bronchodilator Agents
(adverse effects, pharmacology)
- Humans
- Pulmonary Disease, Chronic Obstructive
(drug therapy, metabolism)
- Scopolamine Derivatives
(adverse effects, pharmacology)
- Tiotropium Bromide
|